Protocol summary

Study aim
Determining the effect of inhaled salbutamol on respiratory distress in term infants with transient tachypnea of ​​the newborn admitted to the neonatal intensive care unit
Design
This study is a Phase II triple-blind randomized clinical trial designed to evaluate the efficacy and safety of inhaled salbutamol in full-term neonates with transient tachypnea of the newborn. Eligible neonates are enrolled after obtaining written parental consent and are randomly allocated into intervention and control groups using block randomization. The intervention group receives inhaled salbutamol, while the control group receives placebo. Respiratory and clinical outcomes are assessed before and after intervention, and data are analyzed using STATA software
Settings and conduct
Clinical trial – Shahid Madani Hospital and Shahid Rahimi Hospital
Participants/Inclusion and exclusion criteria
Gestational age greater than 37 weeks. Tachypnea with more than 60 breaths per minute within the first 6 hours of life. Chest X-ray findings including
Intervention groups
Intervention group A receives inhaled salbutamol (Ventolin) at a dose of 0.1 mg/kg, while the control group receives a placebo consisting of 0.1 mg/kg of distilled water.
Main outcome variables
Salbutamol Duration of tachypnea Duration of oxygen therapy Duration of assisted ventilation Time from birth to initiation of feeding Length of hospital stay Gender Oxygen saturation (%) Heart rate Respiratory rate Respiratory distress score Type of delivery Neonatal weight

General information

Reason for update
Acronym
TTN
IRCT registration information
IRCT registration number: IRCT20250722066594N1
Registration date: 2026-10-20, 1405/07/28
Registration timing: prospective

Last update: 2026-10-20, 1405/07/28
Update count: 0
Registration date
2026-10-20, 1405/07/28
Registrant information
Name
Zeynab PirdadehKHani
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 66 0000 0000
Email address
zpirdadeh@yahoo.com
Recruitment status
recruiting
Funding source
Expected recruitment start date
2026-10-23, 1405/08/01
Expected recruitment end date
2026-12-22, 1405/10/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
The effect of salbutamol nebulized on respiratory distress in term infants with transient neonatal tachypnea admitted to the NICU
Public title
The effect of salbutamol nebulizer on respiratory distress in term infants with transient neonatal tachypnea admitted to the NICU
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Gestational age is greater than 37 weeks. Tachypnea with more than 60 breaths per minute in the first 6 hours Lung radiography findings include: congestion and prominence of the navel of the lungs, flattening of the diaphragm, airiness of the lungs, pleural effusion, filling of the horizontal and oblique fissures between the lung lobes.
Exclusion criteria:
Congenital abnormalities Birth Asphyxia Meconium Aspiration Syndrome Congenital Heart Diseases Based on Echocardiography Respiratory Distress Syndrome (RDS)
Age
From 1 day old to 1 day old
Gender
Both
Phase
2-3
Groups that have been masked
  • Participant
  • Care provider
  • Investigator
Sample size
Target sample size: 116
Randomization (investigator's opinion)
Randomized
Randomization description
A triple-blind, randomized clinical trial will be conducted on newborns. In the first stage, participants will be selected via purposive sampling from among those who meet the study's inclusion criteria and for whom parents have provided written informed consent. Participants will then be randomly assigned to either an intervention group or a control group using a balanced block randomization method (with a block size of four). Randomization will be performed prior to the commencement of participant recruitment; codes—designated as 'A' (intervention group) and 'B' (control group)—will be established, and their sequence determined. Specifically, the following four-item combinations will be generated: AABB, ABAB, ABBA, BABA, BBAA, and BAAB. A six-sided die (numbered 1 through 6) will then be used to randomly select these combinations, thereby establishing the allocation sequence (the allocation list) for assigning individuals to the intervention and control groups. The allocation list will be kept confidential by the physician (principal investigator). It should be noted that randomization will be performed separately for each hospital (Shahid Rahimi and Shahid Madani). Once an individual is determined by the physician (principal investigator) to be eligible for the study, they will be assigned to the appropriate group based on the allocation list. To ensure that neither the parents nor the assessor are aware of the group assignment, each study participant will be assigned a random, non-sequential four-digit number, which will be recorded in the allocation list. The physician will document this four-digit number in the participant's medical record. The team’s statistician, who is responsible for data analysis, will have no direct contact with the participants and will not be involved in data collection.
Blinding (investigator's opinion)
Triple blinded
Blinding description
In this study, a triple-blind design is employed (involving parents/participants, the outcome assessor, and the statistical analyst). Regarding the implementation procedure: the randomization sequence (allocation list) is generated prior to the start of the study, separately for each of the two hospitals (Shahid Rahimi and Shahid Madani). This list is kept confidential by a department supervisor—who has no involvement in recruitment, intervention, assessment, or analysis—and remains inaccessible to the recruiting physician and the assessor. Once an infant is deemed eligible by the physician (supervising faculty member) and parental consent is obtained, the infant is assigned to a group based on the next entry in the allocation list. Consequently, the physician remains unaware of the upcoming group assignment prior to determining eligibility, thereby preventing selective enrollment (allocation concealment). To ensure parental blinding, parents are not informed of their infant’s group assignment. To blind the outcome assessor, each participant is assigned a random, non-sequential four-digit code, which is recorded in the allocation list; the physician enters only this code into the patient’s medical record. Thus, when evaluating outcomes, the assessor encounters only the code, from which the intervention or control group cannot be identified. Both the intervention (inhaled salbutamol) and the control (distilled water) are prepared in identical, unlabeled vials—appearing as clear, colorless solutions—and the method of administration (nebulizer), the device used, and the duration and conditions of the procedure are identical for both groups. The preparation and delivery of the solution, based on the allocation list, are carried out by an independent nurse who is not involved in the assessment of outcomes. The outcome assessor is not present at the bedside during the intervention; instead, they assess the outcomes only after the intervention is complete, using the participant’s four-digit code. Consequently, the assessor cannot determine the participant's assigned group based on the appearance or odor of the medication, nor through the method of administration. Similarly, the statistician responsible for data analysis has no direct contact with the participants and is not involved in data collection. The analysis is performed using the four-digit codes, and the allocation list is not made available to the statistician until the final analysis is complete. In the event of a serious adverse event that necessitates knowledge of the participant's group assignment, the blinding is broken only for that specific individual, subject to approval by the department head. بهینه‌سازی با ChatGPT
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Lorestan University of Medical Sciences
Street address
No. 137, Araste 5, Enghelab ., Khorramabad city
City
KHorramabad
Province
Lorestan
Postal code
1111111111
Approval date
2026-04-28, 1405/02/08
Ethics committee reference number
IR.LUMS.REC.1405.085

Health conditions studied

1

Description of health condition studied
transient neonatal tachypnea admitted
ICD-10 code
P28.5
ICD-10 code description
Respiratory failure of newborn

Primary outcomes

1

Description
Infant respiratory distress score
Timepoint
0-24
Method of measurement
Information collection form

2

Description
duration of infant hospitalization
Timepoint
0-24
Method of measurement
Information collection form

3

Description
duration of oxygen therapy
Timepoint
0-24
Method of measurement
Information collection form

4

Description
time of initiation of enteral feeding
Timepoint
0-24
Method of measurement
Information collection form

5

Description
infant oxygen saturation percentage
Timepoint
0-24
Method of measurement
Information collection form

6

Description
duration of tachypnea
Timepoint
0-24
Method of measurement
Information collection form

7

Description
Duration of oxygen therapy for infants
Timepoint
0-24
Method of measurement
Information collection form

Secondary outcomes

empty

Intervention groups

1

Description
Intervention Group A receives inhaled salbutamol (Ventolin) at a dosage of 0.1 mg/kg. The salbutamol is manufactured by Shahid Ghazi Pharmaceutical Company, with each 2.5 ml ampoule containing 2.5 mg of salbutamol.
Category
Treatment - Drugs

2

Description
Control group B receives a placebo consisting of 0.1 mg/kg of distilled water; 5 mL vials of distilled water produced by Shahid Ghazi Pharmaceutical Company were used.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Shahid Rahimi Hospital, Khorramabad
Full name of responsible person
DR. GHobad Heydari
Street address
Azadi
City
KHorramabad
Province
Lorestan
Postal code
1111111111
Phone
+98 66 0000 0000
Email
zpirdadeh@yahoo.com

2

Recruitment center
Name of recruitment center
Shahid Madani Hospital, Khorramabad
Full name of responsible person
DR. GHobad Heydari
Street address
Emam Hossein
City
KHorramabad
Province
Lorestan
Postal code
1111111111
Phone
+98 66 0000 0000
Email
zpirdadeh@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Khoram-Abad University of Medical Sciences
Full name of responsible person
Dr. Peyman Asteraki
Street address
Enghelab Street
City
KHorramabad
Province
Lorestan
Postal code
6814993165
Phone
+98 66 3312 0172
Email
peymanastaraki@yahoo.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
Personal
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Persons

Person responsible for general inquiries

Contact
Name of organization / entity
Khoram-Abad University of Medical Sciences
Full name of responsible person
Zeynab PirdadehKHani
Position
Doctor
Latest degree
Medical doctor
Other areas of specialty/work
Pediatrics
Street address
Enghelab
City
KHorramabad
Province
Lorestan
Postal code
1111111111
Phone
+98 66 0000 0000
Fax
Email
zpirdadeh@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Khoram-Abad University of Medical Sciences
Full name of responsible person
Zeynab PirdadehKHani
Position
Doctor
Latest degree
Medical doctor
Other areas of specialty/work
Pediatrics
Street address
Enghelab
City
KHorramabad
Province
Lorestan
Postal code
1111111111
Phone
+98 66 0000 0000
Fax
Email
zpirdadeh@yahoo.com

Person responsible for updating data

Contact
Name of organization / entity
Khoram-Abad University of Medical Sciences
Full name of responsible person
Zeynab PirdadehKHani
Position
Doctor
Latest degree
Medical doctor
Other areas of specialty/work
Pediatrics
Street address
Enghelab
City
KHorramabad
Province
Lorestan
Postal code
1111111111
Phone
+98 66 0000 0000
Fax
Email
zpirdadeh@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...